Colorado

  

Disclosures - Colorado, USA

Colorado prescribers: The following information is provided by Halozyme, Inc. as required by Colorado House Bill 19-1131.

Pricing information below reflects Antares Pharma’s Wholesale Acquisition Costs (“WAC”) for XYOSTED. The WAC represents published catalogue or list price and may not represent actual transactional prices.

Price customer pays may vary from the prices listed. Cost of prescription depends on the discount applied, price variations from wholesaler/distributor, or other applicable charges.

XYOSTED WAC Price = $643.13

Pricing as of of 01/06/25

The list below provides the names of generic prescription drugs in the same Therapeutic Class as XYOSTED. Please note that the drugs listed are not necessarily the generic form of XYOSTED.   Rather, these drugs could be the generic form of a non-Antares Pharma drug in the same Therapeutic Class.

This list does not imply that the products listed below are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Generics from the same Therapeutic Class: 
Testosterone enanthate, testosterone cypionate, and testosterone undecanoate

Source: AnalySource® 2/19/2020 as reprinted with permission by First Databank, Inc. 
All rights reserved. ©2023

AFFORDABLE
OPTIONS:

Educate your patients about our Co-Pay Assistance Program. 

XYOSTED Co-Pay

Your patients may pay as little as $25* for their prescription. 

* Eligibility restrictions apply.

Click for details and to read the terms and conditions. 

no commerical insurance?

XYOSTED4You

Your patients can purchase XYOSTED for $199.00* per month through on of our partnered specialty pharmacies if they have a prescription.*

* Eligibility restrictions apply.

Click for details and to read the terms and conditions. 


XYOSTED® (testosterone enanthate) injection, for subcutaneous use CIII

XYOSTED INDICATIONS AND USAGE

XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

LIMITATIONS OF USE

  • Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established
  • Safety and efficacy of XYOSTED in males less than 18 years old have not been established

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XYOSTED is contraindicated in:

  • Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
  • Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman.
  • Men with known hypersensitivity to XYOSTED or any of its ingredients (testosterone enanthate and sesame oil).

WARNINGS AND PRECAUTIONS

Polycythemia—Increases in hematocrit, reflective of increases in red blood cell mass, may require discontinuation of XYOSTED. Check that hematocrit is not elevated prior to initiating XYOSTED. Evaluate hematocrit approximately every 3 months while the patient is on XYOSTED. If hematocrit becomes elevated, stop XYOSTED until the hematocrit decreases to an acceptable level. If XYOSTED is restarted and again causes hematocrit to become elevated, stop XYOSTED permanently. An increase in red blood cell mass may increase the risk of thromboembolic events.

Venous Thromboembolism (VTE)—There have been post-marketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as XYOSTED.

In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, a randomized, double-blind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone gel was associated with a higher risk of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE (0.9% vs 0.5%).

Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with XYOSTED and initiate appropriate workup and management.

Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer—Patients with BPH treated with androgens are at an increased risk of worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms. Patients treated with androgens may be at an increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens.

Blood Pressure Increase—XYOSTED can increase blood pressure.  Ambulatory blood pressure monitoring (ABPM) demonstrated XYOSTED increased systolic/diastolic BP by an average of 3.9/1.5 mmHg from baseline after 12 weeks of treatment in clinical trials.  In patients with hypertension on antihypertensive therapy, XYOSTED increased the mean systolic/diastolic BP by 3.9/1.3  mm Hg from baseline.  

The  CV risk associated with topical testosterone gel was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes study in men with a history of CV disease or multiple CV risk factors.  In TRAVERSE, topical testosterone gel increased mean systolic blood pressure by 1.8 mmHg from baseline.  However, the incidences of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups (7% for topical testosterone gel vs 7.3% for placebo).

Monitor blood pressure periodically in men using XYOSTED, especially men with hypertension.  XYOSTED is not recommended for use in patients with uncontrolled hypertension.

Abuse of Testosterone and Monitoring of Serum Testosterone Concentrations—Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions.

If testosterone abuse is suspected, check serum testosterone concentrations to ensure they are within therapeutic range. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.

Not for Use in Women—Due to lack of controlled studies in women and potential virilizing effects, XYOSTED is not indicated for use in women.

Potential for Adverse Effects on Spermatogenesis—With large doses of exogenous androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count. Patients should be informed of this possible risk when deciding whether to use or to continue to use XYOSTED.

Hepatic Adverse Effects—Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. XYOSTED is not known to produce these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue XYOSTED while the cause is evaluated.

Edema—Androgens, including XYOSTED, may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia—Gynecomastia may develop and may persist in patients being treated for hypogonadism.

Sleep Apnea—Treatment with testosterone products, including XYOSTED, may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

Lipid Changes—Changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Hypercalcemia—Androgens, including XYOSTED, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Monitor serum calcium concentrations regularly during treatment with XYOSTED in these patients.

Decreased Thyroxine-binding Globulin—Androgens, including XYOSTED, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Risk of Depression and Suicide—Depression and suicidal ideation and behavior, including completed suicide, have occurred during clinical trials in patients treated with XYOSTED. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation or behavior, new onset or worsening depression, anxiety, or other mood changes.

ADVERSE REACTIONS

The safety of XYOSTED was evaluated in 2 clinical studies in a total of 283 men who received weekly subcutaneous doses for up to 1 year. All patients were started on 75 mg weekly, then the dose was titrated to 50 mg or 100 mg weekly, as needed, to achieve pre-dose total testosterone concentrations of ≥350 ng/dL and <650 ng/dL.

The most commonly reported adverse reactions (>5%) were: hematocrit increased, hypertension, PSA increased, injection site bruising, and headache.

DRUG INTERACTIONS

Insulin—Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.

Oral Anticoagulants—Changes in anticoagulant activity may be seen with androgens, therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.

Corticosteroids—The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring, particularly in patients with cardiac, renal or hepatic disease.

Medications that May Also Increase Blood Pressure—Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with XYOSTED may lead to additional increases in blood pressure.

USE IN SPECIFIC POPULATIONS

Pregnancy—XYOSTED is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies and its mechanism of action. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies.

Lactation—XYOSTED is not indicated for use in females.

Females and Males of Reproductive Potential - During treatment with large doses of exogenous androgens, including XYOSTED, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis. Reduced fertility is observed in some men taking testosterone replacement therapy. The impact on fertility may be irreversible.

Pediatric Use—Safety and effectiveness of XYOSTED in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

Geriatric Use—There have not been sufficient numbers of geriatric patients in controlled clinical studies with XYOSTED to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. Of the 283 patients enrolled in the 6-month and 1-year efficacy and safety clinical study utilizing XYOSTED, 49 (17%) were over 65 years of age. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer. Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH.

DRUG ABUSE AND DEPENDENCE

XYOSTED contains testosterone enanthate, a Schedule III controlled substance in the Controlled Substances Act.

Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids, may be abused by athletes and bodybuilders.

Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids, and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression.

The following adverse reactions have been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemia, testicular atrophy, subfertility, and infertility.

The following adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male pattern baldness, and menstrual irregularities.

The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty.

Withdrawal symptoms can be experienced upon abrupt discontinuation in patients with addiction. Withdrawal symptoms include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido, and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses for approved indications have not been documented. 

For more information, call 1-844-XYOSTED (1-844-996-7833).

Please see full Prescribing Information and Medication Guide.

April 2025 Update.

Terms of Use

PLEASE READ THESE TERMS OF USE CAREFULLY!

BY ACCESSING THIS SITE, YOU ACKNOWLEDGE THAT YOU HAVE READ THESE TERMS OF USE, AND UNDERSTAND AND AGREE TO ABIDE BY THEM.

This Terms of Use Agreement (this “Agreement”) describes the terms and conditions applicable to your use of any and all of Antares Pharma, Inc.’s and/or its affiliates (collectively “Antares”) or Antares co-branded websites. If you do not agree to the terms and conditions of this Agreement, please do not use this website. Your use of certain pages or services within this website may be subject to additional terms and conditions. Before being given access to these pages or services, you will be asked to indicate whether you agree to be bound by the additional terms and conditions. If you agree to be bound, you will be given access to the page or service. If you do not agree to be bound, you will not be given access to the page or service.

Antares may at any time revise or modify this Agreement or impose new conditions for use of this website. Such changes, revisions or modifications shall be effective immediately upon notice to you, which may be given by any means including, without limitation, posting on the website or by e-mail. Any use of the website by you after such notice shall be deemed to constitute acceptance of such changes, revisions or modifications. Antares may modify its services at any time.

THIS WEBSITE DOES NOT PROVIDE MEDICAL OR PROFESSIONAL SERVICES ADVICE.

The content on this website is intended to be a general information resource in regard to the subject matter covered, and is provided solely on an “AS IS” and “AS AVAILABLE” basis. You are encouraged to confirm the information contained herein with other sources, and to review the information carefully with your professional health care provider. Antares is not engaged in rendering medical or similar professional services or advice via this website, and the information provided is not intended to replace medical advice offered by a physician. If you desire or need such services or advice, you should consult a professional health care provider. You should not construe Antares’s publication of this content as an endorsement by Antares of the views expressed herein, or any warranty or guarantee of any strategy, recommendation, treatment, action, or application of medication or preparation made by the author of the content.

Scope of Use

Antares invites you to view, use and download a single copy of this website for your informational, personal, non-commercial use. Except as otherwise provided on this page, no part of any content or software on this website may be copied, downloaded or stored in a retrieval system for any other purpose, nor may it be redistributed for any purpose, without the express written permission of Antares. You understand that Antares may discontinue, change, or restrict your use of this website for any reason without notice.

This website is for use by U.S. residents only. By using this website, you represent that you are at least eighteen (18) years old and a United States resident.

No Warranties

ALL CONTENT ON THIS WEBSITE IS PROVIDED TO YOU ON AN “AS IS” “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. ANTARES MAKES NO WARRANTY AS TO THE ACCURACY, COMPLETENESS, CURRENCY, OR RELIABILITY OF ANY CONTENT AVAILABLE THROUGH THIS WEBSITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THE WEBSITE AND THE CONTENT AVAILABLE ON THE WEBSITE IS AT YOUR SOLE RISK. ANTARES MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THE WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT YOU OBTAIN FROM THE WEBSITE IS FREE OF VIRUSES.

The above exclusions may not apply in jurisdictions that do not allow the exclusion of certain implied warranties.

Limitation of Liability

YOUR USE OF THE WEBSITE OR ANY CONTENT ON THE WEBSITE IS AT YOUR OWN RISK. ANTARES SPECIFICALLY DISCLAIMS ANY LIABILITY, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF THE WEBSITE, EVEN IF ANTARES HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INCLUDING BUT NOT LIMITED TO RELIANCE BY ANY PARTY ON ANY CONTENT OBTAINED THROUGH THE USE OF THE WEBSITE, OR THAT ARISES IN CONNECTION WITH MISTAKES OR OMISSIONS IN, OR DELAYS IN TRANSMISSION OF, INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THE WEBSITE OR VIRUSES, WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, WAR, TERRORISM, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF, OR UNAUTHORIZED ACCESS TO THE WEBSITE, OR RELATED INFORMATION OR PROGRAMS.

Indemnification

If you violate any terms of this Agreement or if you misuse this website, you agree to defend, indemnify and hold harmless Antares, its officers, directors, employees, agents and licensees from any and all liability including, without limitation, costs, expenses and attorneys’ fees that arise out of or are related to your violation or misuse.

User Submissions

Certain areas of this website enable you to submit e-mails, or otherwise provide feedback or information to Antares.

You agree that by submitting content:

Trademarks

The trademarks, logos, and service marks (collectively, the “Trademarks”) displayed on this website are registered and unregistered Trademarks of Antares and others. Nothing contained in this website should be construed as granting, by implication, estoppel, or otherwise, any license or right in and to the Trademarks. Unauthorized use of any Trademark may be a violation of federal and state trademark laws.

Copyright

This website is protected by United States’ and foreign copyright laws. Except for your informational, personal, non-commercial use as authorized above, you may not modify, reproduce or distribute the design or layout of the website, or individual sections of the design or layout of the website or Antares logos without Antares’s written permission.

Information, News and Press Releases

The website may contain information, news and/or press releases about Antares. While this information was believed to be accurate as of the date it was prepared, Antares disclaims any duty or obligation to update this information, news or any press releases. Information about companies other than Antares contained in the news, press releases or otherwise, should not be relied upon as being provided or endorsed by Antares.

Links

This Antares website may contain links to websites operated by other parties. The linked sites are not under the control of Antares, and Antares is not responsible for the content available on any other Internet sites linked to this website. Such links do not imply Antares’s endorsement of material on any other site and Antares disclaims all liability with regard to your access to such linked websites. Antares provides links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this website is at your own risk.

Unless otherwise set forth in a written agreement between you and Antares, you must adhere to Antares’s linking policy as follows: (i) any link to an Antares website must be a text only link clearly marked “Antares WEBSITE,” (ii) the appearance, position and other aspects of the link may not be such as to damage or dilute the goodwill associated with Antares’s names and trademarks, (iii) the link must “point” to the root domain name of the Antares website and not to other pages within the website, (iv) the appearance, position and other attributes of the link may not create the false appearance that your organization or entity is sponsored by, affiliated with, or associated with Antares, (v) when selected by a user, the link must display the website on full-screen and not within a “frame” on the linking website, and (vi) Antares reserves the right to revoke its consent to the link at any time and in its sole discretion.

Security

This website may require you to register or obtain a password prior to permitting access to the website or certain services available on this site. You are responsible for maintaining the confidentiality of your registration information and password, and for all uses of your password, whether or not authorized by you.

Location, Governing Law and Arbitration

This website is operated by Antares. The law of the State of Delaware shall govern these terms and conditions, without reference to its choice of law rules. Antares makes no representation that the information in the website is appropriate or available for use in other locations, and access to this website from territories where the content of this website may be illegal is prohibited. Those who choose to access this website from other locations do so on their own initiative and are responsible for compliance with applicable local laws.

Any controversy or claim arising under or related to this User Agreement or Antares’s products and/or services shall be settled by binding arbitration in accordance with the commercial rules of arbitration of the American Arbitration Association. Any such controversy or claim shall be arbitrated on an individual basis, and shall not be consolidated in any arbitration with any claim or controversy of any other party. The arbitration shall be conducted in the State of Delaware, and judgment on the arbitration award may be entered by any court of competent jurisdiction. Either you or Antares may seek any interim or preliminary relief from a court of competent jurisdiction in the state of Delaware, necessary to protect the rights or property of you or Antares pending the completion of arbitration.

Violations and Additional Policies

Antares reserves the right to seek all remedies available at law and in equity for violations of these Terms of Use, including the right to block access from a particular Internet address to the website.

Use of Information

Antares reserves the right, and you authorize Antares, to the use and assignment of all information regarding your use of this website and all information provided by you in any manner consistent with this User Agreement and applicable federal law.

Securities Laws

This website may include statements concerning Antares’s operations, prospects, strategies, financial condition, future economic performance and demand for Antares’s products or services, as well as its intentions, plans and objectives, that are forward-looking statements. These statements are based upon a number of assumptions and estimates which are subject to significant uncertainties, many of which are beyond our control. When used on the website, words like “anticipates,” “expects,” “believes,” “estimates,” “seeks,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements designed to fall within securities law safe harbors for forward looking statements. The website and the information contained herein does not constitute an offer or a solicitation of an offer for sale of any securities. None of the information contained herein is intended to be, and shall not be deemed to be, incorporated into any of Antares’s securities-related filings or documents.

Questions

If you have any questions about these Terms of Use, please contact Antares at +1 (609) 359 3020. For all other inquiries, please contact us through the relevant product, support or Antares website.

Privacy Policy

Effective Date: 1/1/2020 Last Updated: 4/29/2025

APPLICABILITY

This Privacy Policy (“Policy”) describes how Halozyme, Inc. and its subsidiaries and affiliates (“Halozyme”) collects, uses, and discloses personal information it obtains both (i) online through www.halozyme.com and any other website that posts this Policy (collectively, the “Websites”), and (ii) offline in the course of providing our products and services. This Policy does not apply to information we collect from job applicants, employees, or contractors. To view our Job Applicant Privacy Policy, click here, and to view our Consumer Health Data Privacy Policy, click here.

INFORMATION WE COLLECT

The type of personal information we collect about you depends on your relationship with us. It also depends on how you interact with us.

Contact information and account information. We may collect your name, email address, physical address, and phone number. We may also collect your employer’s name and your business contact information. From users of our disposal kit program, we also collect login and password information. We may also collect clinical trial participant identifiers.

Demographic information. We may collect information such as your date of birth and age as well as your zip code and state. 
Eligibility and health information. We may collect information about your health, diagnosis, or treatment as well as health insurance information. We may also collect insurance or financial assistance eligibility information.

Employment information. We collect information about healthcare providers, including their specialties, professional affiliations, state license data, and NPI numbers.

Submitted information. We collect any other information you voluntarily provide to us. For example, if you submit a medical inquiry online or choose to provide a testimonial about your treatment journey.

Site usage information. We collect information about the browser you are using, the sites you came from and where you visit when you leave us, as well as the actions you make while on the Websites. We may also collect information about your operating system, IP address, and device identifiers.  For additional information regarding our use of cookies and other tracking technologies, please see our Cookies & Ad Settings policy. 

WE COLLECT INFORMATION IN A VARIETY OF WAYS

We collect information directly from you. We collect information if you contact us (directly or through our service providers such as our call center), attend an event, or request a product or service from us. We also collect information from you if you sign up for email communications, or otherwise request information from us.  We may also collect information about you that you post on our social media sites or via literature monitoring as part of pharmacovigilance.

We collect information passively. We may use several common tracking tools to collect information automatically about your use of the Websites and your interaction with emails we send to you. Tracking tools include browser cookies and web beacons. 

We collect information about you from others. Business partners such as healthcare providers, pharmacies, insurers, and other funding partners, may provide information about you to us as permitted by law.  We may collect information about providers from public databases and using tools that allow us to match your consumer identifiers with your professional affiliation.
 

HOW WE USE YOUR INFORMATION

We use personal information for the business and commercial purposes outlined here:

We use information to communicate with you. We use your personal information to respond to your requests or questions. We also use it to send you updates and communicate with you about our policies and terms. We may send you surveys or request feedback for market research and product improvement. 

We use the information to provide and improve our products and services. We use your personal information to improve our products, services, programs, and Websites. This includes customizing your experience with us, providing educational information, facilitating patient co-pay assistance program applications and participation, and providing disposal kits. We also use personal information to investigate adverse event reports or complaints. For providers, we may use your information to send you samples or put you in touch with requested resources. 

We use information for marketing purposes. As permitted by law, we may use your personal information to let you know about new products, programs, or services through promotional communications. We also use information to provide you with newsletters or other content we think you may find interesting. We may also use your information to engage in interest-based advertising. This includes serving you with ads that we think are relevant to you based on your browsing habits or online activities. 

We use information to comply with legal and regulatory requirements. We may use your personal information in order to comply with regulatory reporting obligations, such as reporting adverse events. 

We use information to protect ourselves and others. We use your personal information to protect our company. This includes to identify fraud or secure our systems. 

We use information as otherwise permitted by law (or as we may notify you).

HOW WE DISCLOSE INFORMATION

Below, we have explained the categories of entities with whom we might disclose your personal information.

We disclose information within our family of companies. This includes our parent company as well as current and future subsidiaries and affiliates.

We disclose information with vendors and others who perform services on our behalf. We may disclose all categories of personal information with trusted service providers. These include companies who help us deliver our products and services to you. For example, those that help us run the Websites, send communications, and receive and process adverse event and quality control reports.

We disclose information to our business partners. This may include healthcare providers, pharmacies, insurers, and other funding partners. We only make these disclosures as permitted by law. 

We may disclose information when necessary to comply with the law or to protect ourselves. We will transfer information to respond to a court order or subpoena. We will also disclose it if a government agency or investigatory body requests it, or as required to comply with our reporting obligations to regulatory bodies such as the Food and Drug Administration. We may also share information as necessary to protect against legal liability or prevent fraud.

We may transfer information with any successor to all or part of our business. If all or part of our business is sold or otherwise involved in a corporate transaction, we may transfer personal information as part of that transaction to the successor business. 

We may disclose information otherwise with your consent or for other reasons which we may describe to you.

Additionally, Halozyme does not sell personal information for monetary value; however, under certain U.S. state laws, some of our digital advertising and analytics activities may constitute a “sale” or “sharing” of personal information to our third party advertising and analytics partners for purposes of cross-context behavioral advertising (i.e., targeted advertising).

YOU HAVE CERTAIN PRIVACY CHOICES AND MAY HAVE CERTAIN RIGHTS

You can opt-out of certain marketing communications. To stop receiving our marketing emails please email us at the email address noted below or follow the “unsubscribe” instructions in any marketing email you receive from us. If you opt-out of marketing emails you may continue to receive emails from us related to your relationship with us as permitted by law.

You can control cookies and tracking tools. Your browser may give you the ability to control cookies and other tracking tools. Certain browsers can be set to reject browser cookies. We use performance and analytics partners including but not limited to Google Analytics, which employ cookies and similar technologies on the Websites, so that we can compile statistics about site use. To opt-out of Google Analytics, please visit: https://tools.google.com/dlpage/gaoptout. The Websites do not respond to Do Not Track browser signals. In addition, as discussed below, depending on your state of residence, you may have the right to opt-out of targeted advertising activities. 

If you live in California, Connecticut or New Jersey, or a state with a similar law which applies to Halozyme, you have certain additional legal rights.  These rights may include the following.

  1. Right to Confirm / Access / Know. You may have the right to request access to personal information that we hold about you, including details relating to the ways in which we use and share your information. Residents of California have the right to know the categories of personal information we have collected about them, the categories of sources from which the personal information is collected, the categories of personal information sold, shared, or disclosed, the business or commercial purpose for selling, sharing, or disclosing the personal information, and the categories of third parties to whom we have sold, shared or disclosed their personal information. 
  2. Right to Delete. You may have the right to request that we delete personal information we maintain about you.
  3. Right to Correct. You may have the right to request that we correct inaccurate personal information we maintain about you.
  4. Right of Portability. You may have the right to receive a copy of the personal information we hold about you and to request that we transfer it to a third party.
  5. Right to Withdraw Consent to Processing of Sensitive Personal Information. You may have the right to withdraw your consent to the processing of (or limit the use and disclosure of) your sensitive personal information, unless legal or contractual reasons prevent you from doing so. 
  6. Right to Opt-Out. You may have to opt-out of certain uses of your personal information such as for (i) targeted advertising, (ii) “sale” or “sharing” for cross-context behavioral advertising, or (iii) profiling or automated decision-making activities that result in a legal or similarly significant effect on you. Please note that if you visit our Websites with the Global Privacy Control  opt-out preference signal enabled, if required by law, we will respond to that request in a frictionless manner, meaning we will automatically treat this as a request to opt-out of "sale," "sharing," or targeted advertising for the device or browser from which you broadcast the signal. Learn more about the Global Privacy Control here. 
  7. Right to Appeal. You may have the right to appeal our decision if we decline to process your request in part or in full. You can do so by replying directly to our denial. If you are not satisfied with our response to your appeal, you may contact your state Attorney General.

How it works. You can exercise these rights by emailing us at privacy@halozyme.com, calling us at 1-844-855-4256, or using another method specified in this Policy. When you submit your request, depending on the type of request, we may seek to verify your identity before honoring your request. We do this by matching the information you provide with information we already have about you. Please note that these rights are not absolute, they may apply only in certain circumstances and, in certain cases, we may decline your request as permitted by law. For example, in Connecticut, these rights apply only to consumer health data. We will not discriminate against you for exercising your privacy rights.

Third party agents. If you are submitting a request on behalf of an eligible resident, we may ask for additional information to verify your identity. This may include providing proof that you are registered with the Secretary of State to act on someone’s behalf or proof of a power of attorney.

NOTICE AT COLLECTION FOR CALIFORNIA RESIDENTS

In addition to offering certain consumer rights (set forth in the section above), California law requires us to make the following additional disclosures to consumers regarding our privacy practices.

In the last twelve (12) months, the personal information Halozyme has collected falls into the following categories of personal information as defined under California law:

i.    Identifiers and personal information categories listed in the California Customer Records statute, such as name, signature, address, phone number, email address, online identifier, unique identifier, IP address, date of birth, medical information and health insurance information. We collect this category of information directly from you, automatically from your use of the Websites, from our business partners, and from publicly available sources. 

ii.    Commercial information, such as records of personal property, products or services purchased, obtained, or considered, or other purchasing or consuming histories or tendencies. We collect this category of information directly from you and from our business partners. 

iii.    Internet or other similar network activity, such as browsing history, search history, information on a consumer's interaction with a website, application, or advertisement. We collect this category of information automatically from your use of the Websites.

iv.    Geolocation data, such as IP address. We collect this category of information automatically from your use of the Websites.

v.    Sensory data, such as recordings of customer service and pharmacovigilance calls. We collect this category of information automatically.

vi.    Professional or employment-related information, such as employment information and contact information of providers. 

vii.    Inferences drawn from other personal information, such as a profile reflecting a person’s preferences, characteristics, predispositions, behavior, and aptitudes. We create this category of information based on other information we collect about you. 

viii.    Sensitive personal information, such as health data and username and password. We collect health data directly from you, automatically from your use of the Websites, from our business partners, and from publicly available sources. We collect usernames and passwords from users of our disposal kits. Generally, we do not use sensitive personal information to infer characteristics about individuals, but we may draw conclusions about your health status based on your health information. 


To the extent we maintain de-identified personal information, we commit not to attempt to re-identify it, except as permitted by law. 

We keep these categories of personal information as long as necessary or relevant for the purposes for which they were collected or for which we have a legitimate business purpose. We determine the retention period for each category of personal information based on (i) the length of time we need to retain the information to achieve the business or commercial purpose for which it was collected, (ii) any legal or regulatory requirements applicable to such information, (iii) internal operational needs, and (iv) any need for the information based on an actual or anticipated investigation or litigation.

Halozyme uses and discloses this personal information as described earlier in this Policy. In the past 12 months, we have disclosed each of the above categories of personal information to our service providers, and we have disclosed the following categories of personal information to third party business partners for purposes of providing our products and services, including facilitating patient assistance programs, and to regulatory bodies for purposes of complying with legal and regulatory obligations: Identifiers and personal information categories listed in the California Customer Records statute, Commercial information, and Sensitive Personal Information.

Halozyme does not sell personal information, however, as previously discussed, certain of our digital analytics or advertising activities may constitute a “sharing” of personal information for cross-context behavioral advertising under California law. In particular, we may share the following categories of personal information with third party advertising and analytics partners for the purposes of data analytics and cross-context behavioral advertising: Identifiers and personal information categories listed in the California Customer Records statute, Commercial information, Internet or other similar network activity, Geolocation data, and Inferences drawn from other personal information. California residents have the right to opt-out of this sharing as described above. We do not have actual knowledge that we collect, sell, or share the personal information of California residents under the age of 16.

OUR WEBSITES ARE NOT INTENDED FOR CHILDREN

Our Websites are meant for adults. We do not knowingly collect personally identifiable information from children under 16 without parental consent. If you are a parent or legal guardian and think your child under 16 has given us information without your permission, please contact us and we will delete the information.

WE USE REASONABLE SECURITY MEASURES

We use reasonable security measures as required by relevant law that are designed to protect the security of your personal information. You should be aware, however, that no Internet transmission is fully secure. In particular, website and email transmission may not be 100% secure, and you should therefore take care in deciding what information you send to us through these channels.

WE ARE BASED IN THE UNITED STATES

Information we collect may be stored and processed in the United States. The Websites and our products and services are intended for people who are in the United States. If you live outside of the United States, you understand and agree that your personal information may be transferred to the United States. The United States may not afford the same level of protection as the laws in your country. By submitting your information, you agree to the processing of your personal information in the US.

THIRD PARTY SITES 

Our Websites may include links to third party sites. We do not control these third parties. This Policy does not apply to the privacy practices of those websites. Please read the privacy policy of other websites carefully. We are not responsible for the practices of these third party sites.

HOW TO CONTACT US

If you have questions about this Policy or our privacy practices, or if you wish to exercise your privacy choices or rights, you may contact us as follows:

By Mail:
Halozyme Therapeutics
Attn: Legal Department
12390 El Camino Real
San Diego, CA 92130

By Email: privacy@halozyme.com

Via Website: https://halozyme.com/contact/

By Phone: 844-855-4256

WE MAY UPDATE THIS POLICY

We may make changes or updates to this Policy. We will notify you of any material changes to this Policy as required by law. Changes will also be posted on our Websites. Please check our Websites periodically for updates.

Request to Unsubscribe

If you wish to no longer receive future communications from Antares, please fill in your email address below and click Unsubscribe.

Email Address*

Privacy Policy